Antiviral Research Society News Letter · Poster presentations were also organized for the students and research sc holars ... (Noni) for human wellness ´, Dr. Kalpana Luthra, Professor,

Antiviral Society News Letter, Volume 1, Issue 2, Nov 2017

Registered office

Antiviral Research Society

Sir CV Raman-K.S Krishnan International Research

Centre,

Kalasalingam University (Accredited by NAAC “A “Grade)

Anand Nagar, Krishnankoil 626126, Tamilnadu

Editorial Board

Editor- in-Chief

Dr. P. Selvam, M. Pharm., Ph.D., FNABS, FISNS, IRC, Kalasalingam University

Editorial Board Members

Dr. K. Sunder, Director, IRC, KLU

Dr. Raj Kalkeri, Ph.D., SRI, USA

Dr. M. Chandramohan., M.D., Ph.D., F.I.C.C, Madurai

Dr. Ashish Wadhwani. M.Pharm., Ph.D, JSS University

Dr. Rajkamal Tripathi, CSIR-CDRI, Lucknow

Dr. Ashok Sharon, BIT, Ranchi

Dr. K. Rajesh Kumar., THSTI, Faridabad

Dr. M.R. Jeyaprakash, M.Pharm., Ph.D, JSS University

Dr. M. Kasthur Reddy, Makore Labs, Hyderabad

Dr. H. Raghu Chandrasekar, Manipal University, Manipal

Dr. M.B. Viswanathan, Bharathidasan University, Trichy

Antiviral Research Society (AVRS)

Non Profit Research organization for promotion of Antiviral Research and Education

Antiviral Research Society News Letter

Official Publication of Antiviral Research Society

Regn No.144/2016 (TN Society Registration Act)


National Seminar on “RECENT ADVANCES IN ANTIVIRAL DRUG DESIGN AND

DISCOVERY AGAINST EMERGING AND RE-EMERGING VIRAL DISEASES”

Oct 24 & 25, 2017

Organized by

Sponsored by

Highlights of National Seminar




Summary

Sir CV Raman-K. S. Krishnan International Research Centre of Kalasalingam University,

Krishnankoil in association with Antiviral Research Society organized National seminar on

“RECENT ADVANCES IN ANTIVIRAL DRUG DESIGN AND DISCOVERY AGAINST

EMERGING AND RE-EMERGING VIRAL DISEASES” from October 24-25, 2017. The

Seminar was inaugurated by Dr. N. Mathivanan, Director, University of Madras-Guindy

Campus, Chennai. Dr. A. Abdul Hassan Sathali, Principal, College of Pharmacy, Madurai

Medical College, Madurai gave his Chief guest address and Dr. S. Saravana Sankar, Vice

Chancellor delivered the Presidential address and more than 20 leading speakers delivered

lecture on various aspect of antiviral drug discovery and development in five technical

sessions. Dr. P. Selvam, Organising secretary welcomed the gathering and Dr. K. Rajesh

Kumar, Scientist THRSI, New Delhi proposed the vote of thanks. In the inaugural function

special awards were given in various categories. Life time achievement award was given to Dr.

P. Vijayan, JSS COP, Ooty, Outstanding research scientist award to Dr Smitha A

Kulkarni of NARI, Pune and Women in Science award to Dr, Kalpana Luthra, Professor,

AIIMS, New Delhi. Six Fellowships were awarded to Dr. J. Venkat Rao, Dr. Ashish Wadhwani,

Dr. H. Raghu Chandrasekar, Dr. P. Vivekanadhan, Dr. G. Kumaresan and Dr. M. Elan

Chezhian based on the outstanding contribution in various field of antiviral research.

Technical sessions on Basic virology, Drug discovery, vaccine and Drug design organized in

this seminar. Poster presentations were also organized for the students and research scholars

in the area of drug design and development, a total of 60 posters were presented and top ten

posters were selected for awards. Dr. J. Venkat Rao Professor, Manipal University, Welcome

the gathering Dr Akhil C Banerjea from NII, New Delhi and Dr Kalpna Luthra from AIIMS

New Delhi invited as Chief guest for valedictory function, delivered the valedictory address,

release the AVRS official publication Journal of Antiviral Research Society by Prof Kim of


Kalasalingam University and gave ten best poster awards to winners in valedictory function Dr.

K. Palanichelvam, Professor, Dept Biotechnology, proposed the vote of thanks. More than 150

peoples were actively participated, and 50 members from all over the India participated and

benefited from the Seminar.

First session (24.10.2017) started with informative and interactive talks with Keynote address

and three invited lectures. Dr. N. Mathivanan, Director, University of Madras Guindy

campus, Chennai delivered Key Note address on “Therapeutic potentials of Morinda citrifolia

L. (Noni) for human wellness”, Dr. Kalpana Luthra, Professor, Dept of Biochemistry, AIIMS,

New Delhi delivered lecture on “Immunopathogenesis of HIV-1 infection and characterization

of antibody responses in Indian subtype C infected individuals”. Dr. M. Chandramohan.,

Distinguished Professor Medicine, Tamilnadu Dr M.G.R Medical University, Chennai and

Delivered a keynote address on “Radical Cure of Dengue Fever in 24 hours with anchoring

doses of intravenous repurposed antivirals and anti cytokines” and Dr. G. Kumaresan,

Professor and Head, Dept of Genetics, Madurai Kamarajar University, Madurai enlightened

audience with lecture on “Emergence of personal genomics approaches for targeted cancer

therapeutics”.

Scientific session on “Antiviral drug design and development” were organized in this seminar

Dr. M.B. Viswanathan, Professor, Department of Botany, Bharathidasan University,

Tiruchirappalli Chaired the session and delivered keynote address on “Antiviral activity of

PhyllanthusL. (Euphorbiaceae)”. Four lead speakers gave informative lectures on various

aspects of antiviral drug design and development. Mr R. Raghu, Vice President, Schrodinger,

Bangalore delivered lecture on “Computational Drug design in selective inhibitor design for

potential cancer targets and viral targets", Dr. H. Raghu Chandra Sekar, Professor Manipal

University , gave lecture “Anti-Herpes Simplex Virus Drug Discovery”, Dr. Ashish Wadhwani,

Professor, JSS College of Pharmacy, Ooty made presentation on “Zika Virus a booming threat


and it’s Treatments regimens” and Dr. P. Vivekandhan, IIT-D, New Delhi., highlighted the

“G-quadruplexes in virus genomes as potential drug targets”.

Poster presentations were also organized by the organising committee on 24. 10.2017 Where in

participants from different colleges, universities and institutions all over the India had

participated. Around 60 posters were presented and ten posters were selected for the best

poster awards and award with certificates were given to the award winners in valedictory

function.

Second day Scientific sessions (25.10.2017) started with “Antiviral vaccine and Therapeutics”

and chaired by Dr. Akhil C Banerjea, NII, New Delhi, who gave lecture on “Role of small

RNAs in controlling HIV-1 replication”, Dr. K. Rajesh Kumar, Scientist, Translational Health

Science and Technology Institute, Faridabad, talked on “Advancing in antibody generation

technologies against emerging and re-emerging viral diseases”. Dr. J. Venkat Rao , Manipal

University, Manipal highlighted the importance of “SiRNA therapeutics to tackle emerging

viral infections”. Dr. S. Subramanian, Professor, Dept of Biochemistry, Madras University,

Chennai, delivered talk on “Viral infections trigger the incidence of type 1 diabetes mellitus”.

Dr. J. Sridhar, School of Biological Biotechnology, Madurai Kamarajar University, Madurai

emphasized on “Evolutionary dynamics and genomics of Dengue virus serotypes prevalent in

India”

Special Scientific session on “Epidemiology of emerging viral diseases” was chaired by

Dr. S. Subramanian, Professor, Dept of Biochemistry, Madras University, Chennai, and

Dr. R. Paramasivan, Scientist, CME, ICMR, Madurai delivered the keynote address on

“Antiviral against emerging and remerging Vector borne viral diseases: scopes and

challenges ”and Dr.N.Bharathi, Institute of Microbiology, Madurai Medical College, Madurai,


emphasized on “Co-infection outbreak investigated in the insular village at Ramanathapuram

district, Tamil Nadu, India.”

Two day seminar “RECENT ADVANCES IN ANTIVIRAL DRUG DESIGN AND

DISCOVERY AGAINST EMERGING AND RE-EMERGING VIRAL DISEASES” with

lectures from distinguished speakers were brain storming, inspiring and very informative




Inaugural Function




Oct 24-25, 2017

Scientific Sessions – Invited lectures




Oct 24-25, 2017

Scientific Sessions – Invited lecture




Oct 24-25, 2017

Valedictory Function




Oct 24-25, 2017

AVRS 2017 AWARDS/FELLOWSHIPS

NAME OF AWARD AWARDEE AREA OF RESEARCH

Life Time achievement

award

Dr. P. VIjayan

Professor, JSS College of

Pharmacy, Ooty

Viral research

Outstanding research

scientist award

Dr Smitha A Kulkari

Scientist F NARI, Pune

HIV research

Women In science Dr. Kalpna Luthra,

AIIMS,Newdelhi

HIV Vaccine Research

Fellowship Dr . J. Venkat Rao

Professor, MCOPS, Manipal

University, Manipal

Biotechnological Research

and Drug Design

Fellowship Dr.Raghu Chandrasekar H.

Professor, MCOPS, Manipal

University, Manipal

HSV Drug discovery

Fellowship Dr. G. Kumaresan

Dept Genetics, Madurai

Kamarajar University,

Madurai

Cancer Genomic Research

Fellowship Dr. Elan Chezhian

Prof and Head

Dept of Microbiology,

University of Madras

Hepatitis Research

Fellowship Dr. Ashish Wadhwani

Professor, JSS College of

Pharmcy, Ooty

Biotechnological Research

Fellowship Dr. P. Vivekanadhan

Dept Biosciences, IIT-D,

Newdelhi

Hepatitis Research




Oct 24-25, 2017

Life Time Achievements Awards 2017 Women in Science Awards 2017

Outstanding Research Scientist Awards 2017




Fellowship Awards of Antiviral Research Society 2017




Best Poster Presentation

S.

No.

Name of the

Participant

Name of the Institution Title of the Presentation

1. Aditya Kiran, G. Manipal University,

Karnataka.

Design and Synthesis of Silver

Nanoparticles of Andragraphis

Paniculata as Potential Anticancer

Agents

2. Sakthi Dasan, P. Bharathidasan University,

Trichy.

Antibacterial Activity of the Leaf

Extracts in Wrightia Tinctoria R.Br.

(Apocynaceae)

3. Roshana Devi, V. University of Madras,

Chennai

GTF-231, A Mixture of Gymnemic Acid,

Trigonelline and Ferulic Acid

Significantcy Ameliorates Oxidative

Stress in HFD Fed-Low Dose STZ

Induced Experimental Type-2 Diabetes

in Rats

4. Saravanan, G. MNR College of

Pharmacy, Hyderabad,

Telangana.

Design and Synthesis of New

Quinazolinyl Thiosemicarbazides for

their Anti-Microbial Activities

5. Kavitha, M. Arulmigu Kalasalingam

College of Arts and

Science, Krishnankoil.

Antiviral Activity of Chemokine

Receptor Antagonist (CCR5) Against

HIV

6. Beula Evangeline, C. JSS College of Pharmacy,

Ooty.

Zika Virus A Booming Threat and It’s

Treatment Regimens

7. Vasudha Anisetty JSS College of Pharmacy,

Ooty.

Efficacy of Sida Cordifolia L. Extract

Against Herpes Simplex Virus Type-1

Infection In Vitro and In Vivo

8. Gasim Hassan Nova College of

Pharmaceutical Education

and Research,

Vijayawada, Andhra

Pradesh.

Antibody Therapy Targeting the CD47

Protein is Effective in a Model of

Aggressive Metastatic Leiomyosarcoma

9. Ashok Kumar, N. Madurai Medical College,

Madurais.

Synthesis, Characterization and their

Biological Evaluation of 3(4- Substituted

Phenyl)-Azo-8-Aldehydo-4-Methyl

Coumarin Derivatives

10. Karthik Balakrishnan Madurai Kamarajar

University, Madurai.

Molecular Cellular Analysis of Selected

Food Additives for their Impact on Wnt

Signalling Pathway in Human Stomach

Cancer Cells




Oct 24-25, 2017

Best Poster Presentation Awards 2017




Oct 24-25, 2017

Best Poster Presentation Awards 2017


Invited Article

Novel Protocol Treatment of Dengue Fever & Swine Flu-A (H1N1)

M. Chandramohan1, S.C. Vivekananthan

1, D. Sivakumar

1, P. Selvam

1,

2Nova College of Pharmaceutical Education and Research,

Jafferguda, Hyderabad, Telungana.

Introduction:

Amidst the gloomy situation of declaration of India as “HYPER ENDEMIC” for dengue fever with

yearly average incident of 19775 with mortality of 111.5 in India with worldwide incidence mounting to 100

million and mortality is abort 12% with endemicity occupying in more than 100 countries; we see literature

reports as late as 13th march 2013 stating that there is no specific drugs available for dengue fever;

consonance with the same mood the entire world’s Medical Fraternity is lamenting the same.

With anguish we wondered “How this is happening in this NEW MILLENNIUM” which has ushered in most

advanced scientific methods in diagnosis and treatment. We wanted to conquer this dreaded infection and

initiated methodical analysis of path physiology of the disease and causes of severe manifestations of the

disease namely Dengue haemorrhagic fever [DHF] and Dengue Shock Syndrome [DSS] and propensity for

mortality and morbidity.

This flavivirus, dengue encompasses four serotype namely D1, D2, D3 & D4. If the infection is from one

serotype with low viral load the manifestation will be mild fever and ends up as self liming disease or

undetected sub clinical form. Trouble starts with one serotype infection followed by 2nd

type with high viral

load and high level of non structural antigen NS1 along with higher than physiological level of secreted

cytokines; Tumour necrosis factor alpha (TNF-alpha) Interleukin 1B [IL-B] and Interleukin-6 [IL-6] may

cause severe manifestation of the disease DHF; when the cytokines level goes up to exponential level they

precipitate “Cytokine Storm” and cause profound damage to microcirculatory systems of all the organs of the

body and reach a point of no return causing DFS, with profound capillary leak, haemorrhage, coagulopathy,

refractory thrombocytopenia and death becomes inevitable .

One other malady in all viral infections especially in susceptible children [congenital]or other age group can

progress from cytokine storm to catastrophic “Haemophagocytic Lympho Histiocytosis” manifesting as

uncontrolled indiscriminate phagocytosis of all haemopoitic cell ending in pancytopenia. Without targeting

the above said five precipitating factors, we are at present tackling the disease with symptomatic and

supportive measures along with trying in futile to control the vector mosquitoes Aedes Aegypti and Aedes

Albopictus. We sat down to search world literature through the internet targeting the virus for antivirals and

cytokines for anti-cytokines. As in Biblical verses; “Ask Seek and knock; the door will open” and for us the


door opened and rich haul of details of our choice poured out and we had wide choice to pick and choose. We

had chosen two already in use drugs for long time and had shown to have functional metamorphosis as

antiviral agents; namely Chloroquine [CQ] and S-Adenosyl L-Methionine. We tagged on to these Ribavirin;

well known broad spectrum antiviral agent. While picking anti-cytokines, we chose again two drugs already

in use for other indications and shown to have functional metamorphosis as anti-cytokines namely CQ again

and Doxycycline; to these two anti-cytokines we selected and added Zileuton, Monteleukast and Zaltoprofen.

Modes of Anti Dengue virus actions:

1. Chloroquine: Chloroquine [CQ] had been shown to have 13 modes of antiviral actions as per

literature survey against 13 human pathogenic viruses from 1990 and our valuable contribution is

Anti Hepatitis –C virus [HCV] action in Huh 5-2 cell line studies; Chandramohan et al [2006] and

by 3D-Crystallography assay at NS5B polymerase, Periyasamy Selvam et al [2000]. As for anti

dengue virus [DV] action of CQ we gathered four good scientific reports as early as in 1990 by

Randolph VD et al spelled out that CQ inhibits proteolytic processing of Flavivirus PrM proteins to

as late as 2011; CQ blockade of NS3 of DV as shown by the Novartis institute of Tropical Medicine,

Singapore; in addition two more cell line studies by Navarro-Sanchez 2003 and Johan Nytes.

2. S-Adenosyl L.Methionine [SALM]

Lim SV et al 2011 had shown that SALM binds at NS5 Methyl Trasferace and blocks the D.V

attachment and viral entry into the target cells and terminates viral replication. They have spotted the

compound by virtual screening based on the matching of structural configuration in 5 million

chemicals

3. Ribavirin [RV]

Thakampuniya et al 2011 had shown that broad spectrum antiviral agent Ribavirin blocks DV

replication in MK2 cell line at 50.9 Mµ concentrations

Anti-Cytokines Actions

1. Chloroquine again hold another useful action of anti-cytokine activity as shown by (Jang CH et al 2006,

Weber SM, 2000) So CQ had Dual Anti DFV action, that is antiviral and anti-cytokine action to our

advantage. Another plus point is; it is available as injectable form which can be used in patients with

vomiting and diarrhea. Dose 5mg /kg oraly and 2mg/kg IM o.d

2. The popular antibiotic Doxycyline had been shown by (Castro et al [2011]) that it blocks TNF-α, IL B1

and IL6. Dose 100mg b.d

3. Zileuton; anti asthmatic agent is having good anti-cytokine action namely blockage of synthesis of

cystienyl leukotrine and leukotrine B4 and can be used beneficial for DFV infection. Dose: 600mg b.d

Monteleukast

Cysteinyl L Receptor – Antagonist

Zaltoprofen

Preferential Cox-2 blocker acting at the site of inflammation only

We launched a two pronged attack on DV infection and cytokine excess state with a scientific and judicious

combination of three antiviral agents acting at different sites of replication with additive action, along with


five anti cytokines and anti inflammatory agents again acting at different levels with additive actions has

formed a formidable therapeutic combipack. We formulated a strategy to start the whole set of antivirals and

anticytokines from “DAYONE” of disease of DV infection so that both viral load and cytokine level will not

escalate and we will be able to win the battle against DV with ease and certainty.

Anti-Swine Flu A-H1N1 Programme:

In the same spree we culled out again two already in use drugs Chloroquine [CQ] antimalarial and

Nitazoxanide [NTZ] Antiprotozoal which are shown to have functional metamorphosis as Anti-A[H1N1]

Anti-A H1N1 action:

Chlroquine blocks the M2 channels of A[N1H1] and prevents attachment and cell entry of the targeted host

cells.

Nitazoxanide –NTZ had been shown to block maturation of Haemagglutinin surface antigen of the virus, 500

in number and wholesomely prevents virus attachment on to the targeted cell’s receptor sites, endocytosis,

trafficking inside the Nucleus of the cell, collecting essential materials for assembly of the virus, maturation

of the virus and final process of exocytosis.

These two Anti-A[H1N1] drugs have additive and complementary actions and when added with the

five anti-cytokines combination will work in consonance and will have lethal blow on the virus and prevent

cytokine excess or cytokine storm and will cure the patients radically. I have put up this proposal to W.H.O in

2009 itself for trial and implementation and got a pleasant reply that “Clinical Task Force considering with

attention to your proposal; thank you sharing your ideas with us”; no further communication followed.

New protocol treatment for Dengue Viral Fever

Material and Method:

Recruited 3 male 3 female patients; age ranged between 16 and 36, who had fever, with conjunctival

injection, body pain and retrobulbar pain who were positive for NS1 antigen by rapid card test and the same

remaining sera tested for anti dengue anti bodies IgM and IgG by ELISA assays proved positive denoting that

all the patients had been suffering from secondary dengue infection.

All the seven drugs were given from the day one of the diagnosis in the following oral dose schedule

1. CQ 300mg o.d 2.SALM 400 TDS 3) RV 200mg QID 4) Doxycycline 100mg b.d 5) Zileuton 600mg b.d 6)

Monteleukast 10mg o.d 7) Zaltoprofen 80 tds

We found the fever and other symptomatologies abated in 5 to 14 days while dengue IgM and IgG

ELISA assay had been repeated on every 4 to 6 days. To our surprise; an eye opener result noticed in these

six patients and the Dengue Anti IgM and IgG rendered negative in 16 to 30 days by ELISA assay while the

antibodies usually persist in the blood for 90 days and lifelong respectively.

Conclusion:

These results denote that prompt two prong attack on dengue virus and the illness with multimodal action


might have drastically restricted the DV load and yielded minimal anti bodies production which were cleared

very early and interpreted as “RADICAL CURE” It is heartening to note that among the pessimistic attitude

and lamenting medical fraternity that there is no specific anti viral agent available we have picked up

effective and economical anti viral agents against DV and very effective anti cytokine combination tackling

the Dengue disease manifestations successfully. In both the programmes the antivirals should be used as

prophylaxis for all the inmates of the premises of the patients. In case of severe refractory thrombocytopenia

patient we have given intravenous Anti-D immunoglobulin 50µg/kg for 2 days and shown remarkable

recovery (Gaurav Kharya et al 2011).

These two programmes exemplifies “BENCH TO BED SIDE” motto of utilizing the laboratory

proved benefits to be made available to sick patients in the hospital beds as early as possible.

References:

1. Castro JE et al “Modulation of cytokine and cytokine receptor/antagonist by treatment with

Doxycycline and Tetracycline in patients with dengue fever” Clin Dev Immunol. 2011;2011:370872

2. Chandramohan M, Vivekananthan SC, Sivakumar D, Selvam P, Neyts J, Katrien G, De Clercq E

“Preliminary report of anti – hepatitis C virus activity of chloroquine and hydroxychloroquine in Huh

– 5 – 2 cell line” Indian J. Pharm.Sci. 2006, 68(4): 538 – 540.

3. Chandramohan, M et al “Chloroquine therapy in viral hepatitis” Pro. Southern regn conference of

Association of Physicians of India. Madurai PP. 22 – 1980

4. Jang CH et al., “Chloroquine Inhibits Production of TNF-alpha, Il-1beta and Il-6 from

lipopolysaccharide-stimulated human monocytes/macrophages by different modes” Rheumatology

[Oxford] 2006; 45(6) 703-10

5. Jean Franc¸ois Rossignol “Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral

Hemagglutinin at the Post-translational Level” 2009 284: 43 23, PP29789 – 808 J. Biol. Chem

6. Kharya G et al “Management of severe refractory thrombocytopenia in dengue hemorrhagic fever

with intravenous anti-D immune globulin” Pediatr Hematol Oncol. 2011;28(8):727-32

7. Lango D.L., D.L. Kasper, et al “Harrison’s Principles of Internal Medicine” 18th Edition 2012 pp

1621 publisher M.C. Graw-Hill Company Inc. Newyork U.S.A.

8. Lim SV, Rahman MB, Tejo BA “Structure-based and ligand-based virtual screening of novel

methyltransferase inhibitors of the dengue virus” BMC Bioinformatics. 2011 Nov 30;12 Suppl

13:S24


9. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, et al. (2003) Dendritic-cell-

specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic

cells by mosquito-cell-derived dengue viruses. EMBO Rep 4: 723–728.

10. P. Selvam, Chandramohan,M. Suresh kumar et al “Design, Molecular Modelling Studies on

Chloroquine and Its analogues as Inhibitors of HCV NS5B RNA Polymerase ” 22nd

International

Conference - Antiviral Research 82(2009) A52

11. Periyasamy Selvam, Priya Srinivasan, Tanvi Khot, R. Padmanaban, M. Chandramohan “Studies of

Dengue NS3 Protease Inhibitory Activity of Novel Isatin Derivatives” 25th International Conference

on Antiviral Research – Abstract 99-2012

12. Randolph VB, Winkler G, Stollar V (1990) Acidotropic amines inhibit proteolytic processing of

flavivirus prM protein. Virology 174: 450–458.

13. Ratree Takhampunya et al “Inhibition of dengue virus replication by mycophenolic acid and

ribavirin” Journal of General Virology (2006), 87, 1947–1952

14. Weber SM, Levitz SM (2000) Chloroquine interferes with lipopolysaccharide induced TNF-alpha

gene expression by a nonlysosomotropic mechanism. J Immunol 165: 1534–1540.

15. WHO: Technical Guides for Diagnosis Treatment, Surveillance, Prevention and Control of Dengue

Hemorrhagic Fever, WHO Geneva, 1975.

Dr. M. Chandramohan MD., Ph.D., F.I.C.C

Distinguished Professor TN Dr. MGR Medical University/ Stem Cell Therapist

Chairman & Prof. of Hepatology, Bharat Ratna Kamarajar Jaundice, Liver Hospital and

Research Centre, Retd. Addl.Prof. & HOD of Internal medicine Research Wing, Madurai Medical

College


Documents

Antiviral Research Society News Letter · Poster presentations were also organized for the students and research sc holars ... (Noni) for human wellness ´, Dr. Kalpana Luthra, Professor,